Weekly Reports | Oct 11 2019
Our top ten news from 03 October 2019 to 10 October 2019 (ranked according to popularity).
Tuesday 08 October 2019 – 11:14 AM
Going nowhere. Uranium prices continue to rise and fall but it remains a case of failure to launch.
Friday 04 October 2019 – 10:31 AM
A new report reveals what investors may already know, that "fees make all the difference" to final outcomes for superannuation members' retirement savings, with many funds struggling to generate returns strong enough to cover the negative impact of high investment fees.
Thursday 03 October 2019 – 12:36 PM
A new specialty female oral contraceptive will grace the portfolio of Mayne Pharma, providing a substantial growth opportunity in the medium-long term.
Friday 04 October 2019 – 01:55 PM
As a record low cash rate prevails, amid weak consumer and business sentiment and only muted improvements in housing activity, Australia's major banks are being squeezed mercilessly.
Wednesday 09 October 2019 – 10:00 AM
The New Criterion's Tim Boreham highlights several listed "penny dreadfuls" that may prove not to be so dreadful after all.
Thursday 03 October 2019 – 10:00 AM
The New Criterion's Tim Boreham notes massive legal settlements in the US have highlighted the scourge of opioid abuse, but Australian producer Palla Pharma is confident the drug class will remain the world's foremost pain medication.
Friday 04 October 2019 – 10:00 AM
Weekly Broker Wrap: petrol; infant formula; housing & cash rates; wealth managers; platforms; and childcare.
Thursday 03 October 2019 – 10:37 AM
The Chartist suggests recent consolidation for the iron ore price implies risk remains to the upside.
Tuesday 08 October 2019 – 01:45 PM
EclipX Group is reverting to focus on its core fleet and novated leasing businesses, and interest in the company is only expected to grow.
Tuesday 08 October 2019 – 10:00 AM
Weekly update on stockbroker recommendation, target price, and earnings forecast changes.